BioVaxys Technology Corp (CSE:BIOV) (FRA:5LB) (OTCQB:BVAXF), a clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics, announced on Thursday its acquisition of clinical study management company TAETSoftware Corp.
Based in Vancouver in British Columbia, Canada, TAETSoftware is engaged in the development and commercialisation of the Trial Adverse Events Tracker (TAET) technology platform, a proprietary software application designed to enable clinical study subjects to record and submit reports of adverse events and/or side effects to study sponsors in real time.
In exchange for all of the issued and outstanding shares of TAETCo, BioVaxys issued 24,500,000 common shares to TAETCo shareholders. An additional 2,500,000 common shares will become payable upon the successful testing of the beta version of the application.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine